Axitinib is a small molecule tyrosine kinase inhibitor. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) modelsand has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
1.product name :Axitinib
2.Grade Standard:Medicine Grade
8.Delivery time:within 3 days
Axitinib is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in people who have not been treated successfully with another medication. Axitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells